Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Eiry Roberts Sells 2,632 Shares

Posted by Emily Schoerning on Jan 14th, 2021

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Eiry Roberts sold 2,632 shares of the stock in a transaction that occurred on Friday, January 8th. The stock was sold at an average price of $111.06, for a total transaction of $292,309.92. Following the completion of the transaction, the insider now owns 15,845 shares in the company, valued at approximately $1,759,745.70. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Neurocrine Biosciences stock opened at $108.15 on Thursday. The company’s fifty day moving average price is $97.98 and its 200 day moving average price is $106.30. The stock has a market capitalization of $10.10 billion, a P/E ratio of 116.29 and a beta of 1.00. Neurocrine Biosciences, Inc. has a 1 year low of $72.14 and a 1 year high of $136.26.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Saturday, November 14th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.11 by ($0.73). Neurocrine Biosciences had a net margin of 8.96% and a return on equity of 18.18%. The company had revenue of $258.80 million during the quarter, compared to analyst estimates of $282.59 million. During the same quarter last year, the business earned $0.56 EPS. The firm’s revenue for the quarter was up 16.5% compared to the same quarter last year. On average, sell-side analysts predict that Neurocrine Biosciences, Inc. will post 1.28 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of NBIX. American International Group Inc. boosted its position in shares of Neurocrine Biosciences by 21.1% in the second quarter. American International Group Inc. now owns 2,516 shares of the company’s stock worth $307,000 after buying an additional 438 shares during the period. Balyasny Asset Management LLC bought a new position in shares of Neurocrine Biosciences in the 2nd quarter worth about $348,000. Glenmede Trust Co. NA boosted its holdings in shares of Neurocrine Biosciences by 36.2% in the 2nd quarter. Glenmede Trust Co. NA now owns 26,233 shares of the company’s stock valued at $3,200,000 after buying an additional 6,971 shares during the period. Private Advisor Group LLC bought a new stake in shares of Neurocrine Biosciences during the 2nd quarter valued at about $124,000. Finally, Great West Life Assurance Co. Can raised its stake in Neurocrine Biosciences by 12.5% during the second quarter. Great West Life Assurance Co. Can now owns 35,970 shares of the company’s stock worth $4,367,000 after acquiring an additional 3,991 shares during the period. Institutional investors own 93.23% of the company’s stock.

Several analysts have commented on the stock. William Blair restated an “outperform” rating on shares of Neurocrine Biosciences in a research note on Tuesday, November 10th. Oppenheimer decreased their target price on shares of Neurocrine Biosciences from $150.00 to $145.00 in a research report on Tuesday, November 10th. Benchmark started coverage on Neurocrine Biosciences in a research report on Wednesday, September 30th. They set a “hold” rating on the stock. Wedbush decreased their price objective on Neurocrine Biosciences from $129.00 to $121.00 and set an “outperform” rating for the company in a report on Monday, December 7th. Finally, SVB Leerink lowered their target price on Neurocrine Biosciences from $120.00 to $100.00 and set a “market perform” rating on the stock in a research note on Tuesday, November 10th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $127.45.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc, a commercial-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of neurological, endocrine, and psychiatric disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) for the treatment of tardive dyskinesia; and ORILISSA, a gonadotropin-releasing hormone antagonist for use in the treatment of endometriosis.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Eiry Roberts Sells 2,632 Shares

You might be interested in: